| Not Yet Recruiting | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigen NCT06694454 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Suspended | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 NCT05642195 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung NCT07227025 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Not Yet Recruiting | Intratumoral N17350 in Advanced Solid Tumors NCT07339176 | Onchilles Pharma Inc | Phase 1 / Phase 2 |
| Not Yet Recruiting | Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI NCT07355231 | Xemed LLC | Phase 1 / Phase 2 |
| Not Yet Recruiting | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Y NCT07440290 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different NCT07227298 | Pfizer | Phase 1 / Phase 2 |
| Recruiting | Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemother NCT07222566 | Pfizer | Phase 3 |
| Not Yet Recruiting | Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in NCT07373899 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Recruiting | A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC NCT06908304 | Maia Biotechnology | Phase 3 |
| Recruiting | A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in NCT07230691 | Janssen Research & Development, LLC | — |
| Recruiting | MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients NCT07509333 | West China Hospital | N/A |
| Recruiting | A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants NCT07180862 | Bio-Thera Solutions | Phase 1 |
| Recruiting | A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCL NCT06855771 | Bristol-Myers Squibb | Phase 2 |
| Recruiting | IMPT Dose Escalation for NSCLC (HyDose) NCT06484491 | University Medical Center Groningen | N/A |
| Not Yet Recruiting | Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) NCT07162883 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers NCT07117214 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors NCT07090499 | Pfizer | Phase 1 |
| Not Yet Recruiting | Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NCT07129161 | Sun Yat-sen University | Phase 2 |
| Recruiting | A Study of LY4175408 in Participants With Advanced Cancer NCT07046923 | Eli Lilly and Company | Phase 1 |
| Recruiting | This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizuma NCT06758401 | Pfizer | Phase 3 |
| Active Not Recruiting | A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out. NCT06678555 | Pfizer | — |
| Recruiting | Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost NCT06627738 | Centre Antoine Lacassagne | Phase 2 |
| Recruiting | ALG-LungCancerRegistry (SAFRO2202) NCT07161882 | Société Algérienne de Formation et de Recherche en Oncologie | — |
| Recruiting | A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell NCT06780085 | Merck Sharp & Dohme LLC | Phase 2 |
| Active Not Recruiting | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies NCT06974734 | Pfizer | Phase 1 |
| Recruiting | Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Sta NCT06709859 | Shandong Public Health Clinical Center | Phase 2 |
| Not Yet Recruiting | Personalizing Adoptive Cell Transfer for Solid Tumors: Towards a New Patient-tailored Treatment Option NCT06922266 | Ospedale San Raffaele | — |
| Recruiting | Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adj NCT06862869 | Hoffmann-La Roche | — |
| Recruiting | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in NCT06875310 | Mirati Therapeutics Inc. | Phase 3 |
| Recruiting | A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high NCT06868277 | AstraZeneca | Phase 3 |
| Recruiting | Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresect NCT06890598 | Eli Lilly and Company | Phase 3 |
| Recruiting | A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid NCT06687941 | Aptamer Sciences, Inc. | Phase 1 |
| Recruiting | Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC NCT06623656 | Weill Medical College of Cornell University | Phase 2 |
| Recruiting | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and P NCT06431633 | Fundación GECP | Phase 3 |
| Recruiting | A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemo NCT06667076 | Janssen Research & Development, LLC | Phase 2 |
| Recruiting | Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients NCT06481813 | Nantes University Hospital | N/A |
| Active Not Recruiting | A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in NCT06704724 | Pfizer | Phase 1 |
| Recruiting | A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Sma NCT06667908 | Johnson & Johnson Enterprise Innovation Inc. | Phase 2 |
| Not Yet Recruiting | Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patie NCT06697990 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Active Not Recruiting | Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study NCT06494241 | AstraZeneca | — |
| Recruiting | Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer NCT06566443 | The Methodist Hospital Research Institute | Phase 1 |
| Withdrawn | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357 | Travera Inc | — |
| Recruiting | A Study of DM005 in Patients With Advanced Solid Tumors NCT06515990 | Doma Biopharmaceutical（Suzhou）Co., Ltd. | Phase 1 |
| Recruiting | A Study of DM001 in Patients With Advanced Solid Tumors NCT06475937 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Phase 1 |
| Recruiting | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small C NCT06623422 | Merck Sharp & Dohme LLC | Phase 3 |
| Withdrawn | A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain. NCT06075615 | Pfizer | — |
| Completed | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors NCT06549816 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Active Not Recruiting | A Study of SGN-MesoC2 in Advanced Solid Tumors NCT06466187 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Active Not Recruiting | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases NCT06282874 | Guangdong Association of Clinical Trials | Phase 4 |
| Recruiting | Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC NCT05805631 | Taipei Veterans General Hospital, Taiwan | Phase 2 |
| Active Not Recruiting | Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC NCT06376084 | AstraZeneca | — |
| Active Not Recruiting | A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell L NCT06532032 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Recruiting | The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer NCT06623487 | Ruijin Hospital | — |
| Terminated | A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Partic NCT06280196 | Bio-Thera Solutions | Phase 3 |
| Recruiting | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer NCT06380816 | Cancer Research UK | Phase 1 / Phase 2 |
| Recruiting | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in NCT06447662 | Pfizer | Phase 1 |
| Terminated | A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients NCT06186076 | Therapex Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors NCT06400472 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | QOL After SURGERY and ADJUVANT Treatment NCT06115239 | University of Salamanca | — |
| Recruiting | Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation NCT06269211 | Ruijin Hospital | Phase 2 |
| Active Not Recruiting | A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared NCT06008093 | AstraZeneca | Phase 2 |
| Active Not Recruiting | A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer NCT06012435 | Seagen, a wholly owned subsidiary of Pfizer | Phase 3 |
| Recruiting | Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated NCT06120140 | Janssen Research & Development, LLC | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer NCT06221462 | Ningbo No.2 Hospital | Phase 2 |
| Unknown | Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Fa NCT05248022 | The Central Hospital of Lishui City | N/A |
| Recruiting | A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With A NCT06119581 | Eli Lilly and Company | Phase 3 |
| Active Not Recruiting | A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase NCT06140836 | Bristol-Myers Squibb | Phase 3 |
| Not Yet Recruiting | Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC NCT06127329 | Gang Wu | N/A |
| Recruiting | A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer NCT06116786 | Johnson & Johnson Enterprise Innovation Inc. | Phase 1 |
| Unknown | Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration NCT06281860 | Dr Jean Yannis PERENTES | Phase 1 |
| Recruiting | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Active Not Recruiting | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors NCT05983133 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Active Not Recruiting | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 NCT06003231 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Recruiting | Confocal Laser Endomicroscopy VERification NCT06079970 | Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC) | N/A |
| Unknown | Dietary Practices and Locally Advanced Lung Cancer (LUNGDIET) NCT06068088 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy NCT05715229 | Hackensack Meridian Health | Phase 2 |
| Recruiting | Patient-centered, Optimal Integration of Survivorship and Palliative Care NCT04900935 | Massachusetts General Hospital | N/A |
| Withdrawn | SCION: SABR and Checkpoint Inhibition of NSCLC NCT04944173 | University of British Columbia | Phase 2 |
| Active Not Recruiting | A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery NCT05872763 | Hoffmann-La Roche | — |
| Recruiting | Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCL NCT06001151 | Qian Chu | Phase 2 |
| Active Not Recruiting | Metabolic Response to Food in Lung Cancer NCT05937074 | Pennington Biomedical Research Center | — |
| Recruiting | CIETAI and Sequential Radiotherapy in Squamous Lung Cancer NCT05892237 | Dong Wang | Phase 2 |
| Recruiting | A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC NCT05940532 | Hunan Cancer Hospital | Phase 2 |
| Completed | Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI NCT05826366 | AstraZeneca | — |
| Active Not Recruiting | Premedication to Reduce Amivantamab Associated Infusion Related Reactions NCT05663866 | Janssen Research & Development, LLC | Phase 2 |
| Active Not Recruiting | A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell NCT05908734 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Terminated | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumor NCT05462873 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI NCT05302817 | Xemed LLC | Phase 1 |
| Terminated | A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non- NCT05469178 | BerGenBio ASA | Phase 1 / Phase 2 |
| Recruiting | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Posi NCT05768178 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma NCT05456256 | Lantern Pharma Inc. | Phase 2 |
| Unknown | Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Met NCT05737589 | Xiaorong Dong | — |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab fo NCT05609968 | Merck Sharp & Dohme LLC | Phase 3 |
| Withdrawn | CISH Inactivated TILs in the Treatment of NSCLC NCT05566223 | Intima Bioscience, Inc. | Phase 1 / Phase 2 |
| Recruiting | MYLUNG Consortium Part 3: Observational Study NCT05885698 | US Oncology Research | — |
| Active Not Recruiting | Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCL NCT05401786 | The Netherlands Cancer Institute | Phase 2 |
| Completed | A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Pattern NCT06039683 | AstraZeneca | — |
| Recruiting | First in Human Study of AZD9592 in Solid Tumors NCT05647122 | AstraZeneca | Phase 1 |
| Unknown | Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer NCT05573373 | Affiliated Hospital of Jiangnan University | Phase 1 |
| Active Not Recruiting | A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cance NCT05488314 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Recruiting | A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-sm NCT05487391 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Terminated | A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Ade NCT05577715 | Bristol-Myers Squibb | Phase 2 |
| Recruiting | A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Fac NCT05498428 | Janssen Research & Development, LLC | Phase 2 |
| Unknown | Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF NCT05603013 | Second Affiliated Hospital of Soochow University | Phase 2 |
| Active Not Recruiting | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advance NCT05544929 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Active Not Recruiting | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutati NCT05358249 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung Cancer NCT05599685 | Bristol-Myers Squibb | — |
| Recruiting | A Study of Oncobax®-AK in Patients With Advanced Solid Tumors NCT05865730 | EverImmune | Phase 2 |
| Unknown | Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Can NCT05529355 | Anhui Chest Hospital | Phase 2 |
| Completed | Postoperative Telerehabilitation in Older Adults NCT05435885 | Pusan National University Hospital | N/A |
| Completed | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) NCT05461430 | Travera Inc | — |
| Completed | Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpo NCT05440916 | University Medical Centre Maribor | Phase 2 |
| Active Not Recruiting | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cance NCT05460273 | AstraZeneca | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC NCT05380271 | Gang Wu | Phase 2 |
| Recruiting | THIO Sequenced With Cemiplimab in Advanced NSCLC NCT05208944 | Maia Biotechnology | Phase 2 |
| Terminated | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanc NCT05397171 | AstraZeneca | Phase 1 / Phase 2 |
| Active Not Recruiting | Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC NCT05163249 | Guangdong Association of Clinical Trials | Phase 2 |
| Recruiting | A Real World Study of Ensartinib in Advanced ALK-positive NSCLC NCT05498064 | Peking Union Medical College Hospital | — |
| Recruiting | Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer NCT05260606 | Samsung Medical Center | — |
| Active Not Recruiting | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pe NCT05298423 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer NCT05319574 | Sun Yat-sen University | Phase 2 |
| Terminated | A Study of SGN-ALPV in Advanced Solid Tumors NCT05229900 | Seagen Inc. | Phase 1 |
| Unknown | Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer NCT05306847 | Peking Union Medical College Hospital | Phase 2 |
| Completed | A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer NCT04951154 | Janssen Research & Development, LLC | — |
| Recruiting | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels NCT05525338 | University Medical Center Groningen | Phase 4 |
| Active Not Recruiting | A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Trea NCT05241834 | Eli Lilly and Company | Phase 1 |
| Terminated | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations NCT05241873 | Blueprint Medicines Corporation | Phase 1 |
| Terminated | Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC NCT04925986 | Sarah Goldberg | Phase 2 |
| Recruiting | SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009) NCT04527419 | Fudan University | N/A |
| Recruiting | ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007) NCT03786003 | Fudan University | N/A |
| Unknown | Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer NCT04956146 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Completed | Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation NCT05263947 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Terminated | Predictive Assay for Decision Making in Adjuvant Therapy NCT05032352 | Insight Molecular Diagnostics | — |
| Terminated | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC NCT05153408 | Blueprint Medicines Corporation | Phase 1 |
| Terminated | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors NCT05194072 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Active Not Recruiting | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) NCT04819100 | Eli Lilly and Company | Phase 3 |
| Completed | A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer NCT05250817 | Bristol-Myers Squibb | — |
| Unknown | Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer NCT05003037 | Li Zhang, MD | Phase 2 |
| Active Not Recruiting | Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC ( NCT04597671 | Association NVALT Studies | Phase 3 |
| Active Not Recruiting | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-B NCT04988295 | Janssen Research & Development, LLC | Phase 3 |
| Terminated | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Met NCT05099549 | NKGen Biotech, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastat NCT04984811 | NeoImmuneTech | Phase 2 |
| Completed | A Study of SEA-CD40 Given With Other Drugs in Cancers NCT04993677 | Seagen Inc. | Phase 2 |
| Unknown | Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC NCT05167604 | Tang-Du Hospital | — |
| Active Not Recruiting | A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Meta NCT04603807 | Hoffmann-La Roche | Phase 3 |
| Completed | Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real Wo NCT04948411 | Latin American Cooperative Oncology Group | — |
| Active Not Recruiting | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer NCT04931654 | AstraZeneca | Phase 1 / Phase 2 |
| Active Not Recruiting | Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced No NCT04823377 | Institut Curie | N/A |
| Terminated | Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non- NCT04816214 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers NCT04879849 | Takeda | Phase 1 |
| Recruiting | Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osi NCT04486833 | Genprex, Inc. | Phase 1 / Phase 2 |
| Unknown | A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer NCT05068024 | Forward Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital NCT04884269 | AstraZeneca | — |
| Recruiting | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) NCT04956640 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With D NCT04748419 | University of Nebraska | Phase 1 / Phase 2 |
| Unknown | Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Inserti NCT04974879 | Qingdao Central Hospital | Phase 2 |
| Withdrawn | A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezoliz NCT04611776 | Hoffmann-La Roche | Phase 2 |
| Terminated | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780 | Blueprint Medicines Corporation | Phase 1 |
| Active Not Recruiting | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) NCT04776447 | Fundación GECP | Phase 2 |
| Unknown | An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (N NCT04919616 | Shanghai OriginCell Therapeutics Co., Ltd. | EARLY_Phase 1 |
| Unknown | Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies NCT04878692 | Hospices Civils de Lyon | N/A |
| Unknown | Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Fa NCT04825925 | Tianjin Medical University Cancer Institute and Hospital | N/A |
| Active Not Recruiting | Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and A NCT04432142 | Maastricht Radiation Oncology | — |
| Active Not Recruiting | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation NCT04699188 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Toward High Fidelity Adaptive Radiotherapy in the Thorax NCT04731571 | Henry Ford Health System | — |
| Completed | Feasibility of an Acute Physical Exercise Before Treatment Infusion for Metastatic Lung Cancer Patients NCT04676009 | Centre Leon Berard | N/A |
| Terminated | A Study of SGN-STNV in Advanced Solid Tumors NCT04665921 | Seagen Inc. | Phase 1 |
| Active Not Recruiting | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations NCT04579380 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Terminated | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involveme NCT04543188 | Pfizer | Phase 1 |
| Unknown | Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR NCT05104281 | Qingdao Central Hospital | Phase 3 |
| Completed | A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell NCT04887519 | Takeda | — |
| Active Not Recruiting | MYLUNG Consortium Study Protocol 2 NCT05644808 | US Oncology Research | — |
| Active Not Recruiting | A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemother NCT04794010 | Bristol-Myers Squibb | — |
| Terminated | Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects NCT04515979 | MedPacto, Inc. | Phase 2 |
| Recruiting | Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung NCT04499053 | Georgetown University | Phase 2 |
| Unknown | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patien NCT04697446 | Blueprint Medicines Corporation | — |
| Completed | Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After C NCT04642469 | AstraZeneca | Phase 3 |
| Terminated | Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small C NCT04585815 | Pfizer | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, i NCT04538664 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small NCT04471428 | Hoffmann-La Roche | Phase 3 |
| Unknown | Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastat NCT04255836 | Zhejiang Cancer Hospital | Phase 2 |
| Active Not Recruiting | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic NCT04487080 | Janssen Research & Development, LLC | Phase 3 |
| Suspended | Osimertinib for NSCLC With Uncommon EGFR Mutations NCT05421936 | Sheba Medical Center | — |
| Terminated | Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Ce NCT04427072 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and NCT04452214 | Cantargia AB | Phase 1 |
| Completed | A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV NCT04426825 | Hoffmann-La Roche | Phase 2 |
| Unknown | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell L NCT04838548 | Shanghai Miracogen Inc. | Phase 2 |
| Unknown | Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study NCT04397432 | Tian Xie | — |
| Terminated | Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations NCT04323436 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSC NCT04452877 | Novartis Pharmaceuticals | Phase 2 |
| Withdrawn | NEUWAVE Flexible Probe Study #2 NCT03713099 | Ethicon, Inc. | N/A |
| Unknown | First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting NCT04391283 | First Affiliated Hospital of Zhejiang University | — |
| Terminated | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer NCT04222972 | Hoffmann-La Roche | Phase 3 |
| Unknown | A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies NCT04544748 | AO GENERIUM | Phase 1 |
| Completed | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resecte NCT04385368 | AstraZeneca | Phase 3 |
| Active Not Recruiting | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olapar NCT04380636 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study NCT04115410 | Sungkyunkwan University | — |
| Unknown | Immunotherapy in Lung Cancer: Treatment After IO Cessation. NCT04465942 | European Lung Cancer Working Party | — |
| Completed | Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACI NCT04529564 | AstraZeneca | — |
| Completed | Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma NCT04224337 | Seoul National University Hospital | Phase 2 |
| Recruiting | A Study of Sigvotatug Vedotin in Advanced Solid Tumors NCT04389632 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Drive NCT03958565 | University of Colorado, Denver | — |
| Completed | Why in Hospital After VATS Lobectomy NCT04294108 | Rigshospitalet, Denmark | — |
| Completed | A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy NCT04194203 | Hoffmann-La Roche | Phase 3 |
| Completed | Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil NCT04947683 | Latin American Cooperative Oncology Group | — |
| Terminated | Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in C NCT03996473 | Bayer | Phase 1 |
| Completed | KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational A NCT04165096 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | The Effect of a Combined Drainage Strategy in Uniportal Upper Lung Lobectomy NCT04461652 | Tongji University | N/A |
| Completed | Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer NCT04051827 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy W NCT04165070 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Completed | KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational A NCT04165083 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alon NCT04165798 | Merck Sharp & Dohme LLC | — |
| Completed | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors NCT03023319 | Nagla Abdel Karim | Phase 1 |
| Active Not Recruiting | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by S NCT04025879 | Bristol-Myers Squibb | Phase 3 |
| Completed | A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced NCT04075396 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Unknown | OMEGA, Local Ablative Therapy in Oligometastatic NSCLC NCT03827577 | Azienda Ospedaliera Universitaria Integrata Verona | Phase 3 |
| Recruiting | A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea NCT04592523 | Takeda | — |
| Active Not Recruiting | A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-smal NCT04077463 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chem NCT03995875 | AstraZeneca | — |
| Completed | ctDNA Guided Treatment of Early Resistance to Targeted Treatment NCT04148066 | The Netherlands Cancer Institute | N/A |
| Completed | Stage III NSCLC RWE in Chinese Patients NCT04023812 | AstraZeneca | — |
| Unknown | A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC NCT04023617 | Peking University Cancer Hospital & Institute | Phase 2 |
| Unknown | Adjuvant Chemotherapy With or Without Intercalated Icotinib NCT03983811 | Nanfang Hospital, Southern Medical University | N/A |
| Recruiting | Development and Analysis of a Stool Bank for Cancer Patients NCT04291755 | Persephone Biosciences | — |
| Terminated | Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line NCT03904108 | ROGER S KERESZTES MD | Phase 2 |
| Terminated | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) NCT03948763 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS NCT03918304 | AstraZeneca | — |
| Terminated | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagno NCT03745222 | Celgene | Phase 3 |
| Active Not Recruiting | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tum NCT03891953 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China NCT03909971 | Pfizer | Phase 2 |
| Completed | SinTilimab After Radiation (STAR Study) NCT04167657 | Peking Union Medical College Hospital | Phase 2 |
| Completed | M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) NCT03840915 | EMD Serono Research & Development Institute, Inc. | Phase 1 / Phase 2 |
| Unknown | Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer NCT03871205 | Shenzhen People's Hospital | Phase 1 |
| Terminated | Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer NCT03802058 | Wuhan University | Phase 2 |
| Active Not Recruiting | Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non- NCT03833154 | AstraZeneca | Phase 3 |
| Unknown | NSCLC Isotoxic Hypofractionated Radiotherapy NCT03606291 | The Second Hospital of Hebei Medical University | N/A |
| Unknown | NSCLC Isotoxic Hypofractionated Chemoradiotherapy NCT03606239 | The Second Hospital of Hebei Medical University | N/A |
| Completed | Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non- NCT03715205 | Merck Sharp & Dohme LLC | Phase 4 |
| Terminated | This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients NCT03780725 | Boehringer Ingelheim | Phase 1 |
| Completed | Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH) NCT05321212 | University Hospital, Brest | — |
| Completed | Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer NCT03647488 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MI NCT03975114 | National Cancer Institute, Naples | Phase 2 |
| Unknown | Influence of Biopsy Technique on Moleculargenetic Tumor Characterisation in NSCLC NCT03971175 | University Hospital Tuebingen | N/A |
| Terminated | T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive N NCT03784599 | The Netherlands Cancer Institute | Phase 2 |
| Unknown | Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC NCT03884192 | Shandong Cancer Hospital and Institute | Phase 3 |
| Unknown | Aggressive Thoracic Radiotherapy for Stage Ⅳ Non Small Cell Lung Cancer NCT03565120 | yu gengsheng | N/A |
| Unknown | Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutation NCT03799094 | Clifford Hospital, Guangzhou, China | Phase 1 / Phase 2 |
| Completed | Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lu NCT03727724 | The Netherlands Cancer Institute | Phase 2 |
| Withdrawn | A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavir NCT02531854 | Advaxis, Inc. | Phase 2 |
| Completed | Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients NCT03721289 | AstraZeneca | — |
| Active Not Recruiting | A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients NCT03706690 | AstraZeneca | Phase 3 |
| Terminated | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non- NCT03663166 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC NCT02905591 | Joseph J. Cullen, MD, FACS | Phase 2 |
| Completed | Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIV NCT03669523 | Centre Hospitalier Annecy Genevois | Phase 2 |
| Completed | Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC NCT03712969 | West China Hospital | Phase 4 |
| Unknown | Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients NCT03672136 | Shandong Cancer Hospital and Institute | Phase 2 |
| Active Not Recruiting | Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitiv NCT03740126 | Rigshospitalet, Denmark | N/A |
| Completed | IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Ther NCT03643484 | AstraZeneca | — |
| Unknown | Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC NCT03700333 | The First Affiliated Hospital with Nanjing Medical University | Phase 3 |
| Completed | Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium NCT03761901 | AstraZeneca | — |
| Completed | Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer and Discovery of New Biomarkers NCT03658460 | Aalborg University Hospital | — |
| Active Not Recruiting | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive NCT03456076 | Hoffmann-La Roche | Phase 3 |
| Recruiting | Osimertinib In EGFR Mutant Lung Cancer NCT03586453 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC NCT04170959 | ethisch.comite@uza.be | Phase 2 |
| Withdrawn | Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NCT03529084 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With NCT03546894 | Takeda | — |
| Completed | Radiomics Multifactorial Biomarker for Pulmonary Nodules NCT03872362 | Maastricht University | — |
| Unknown | Phase II Umbrella Study Directed by Next Generation Sequencing NCT03574402 | Guangdong Association of Clinical Trials | Phase 2 |
| Completed | E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C NCT03623750 | Instituto Oncológico Dr Rosell | Phase 1 / Phase 2 |
| Terminated | NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung NCT03603652 | Ethicon, Inc. | N/A |
| Terminated | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung C NCT03580694 | Regeneron Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors NCT03485209 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Withdrawn | Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carbo NCT03498222 | Queen Mary University of London | Phase 1 |
| Active Not Recruiting | Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel NCT03381274 | MedImmune LLC | Phase 1 / Phase 2 |
| Completed | A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer NCT03380871 | BioNTech US Inc. | Phase 1 |
| Completed | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors NCT03509012 | AstraZeneca | Phase 1 |
| Completed | A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer NCT03446417 | Zeno Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Block NCT03233724 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Unknown | Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) NCT03432156 | Beijing Friendship Hospital | Phase 2 |
| Recruiting | National Network Genomic Medicine Lung Cancer, Germany NCT05934032 | Prof. Dr. Juergen Wolf | — |
| Completed | G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer NCT03455829 | G1 Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA N NCT03479294 | West China Hospital | — |
| Terminated | Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer NCT03460678 | Hikma Pharmaceuticals LLC | Phase 4 |
| Completed | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With A NCT03396445 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients NCT03489616 | Shandong Cancer Hospital and Institute | N/A |
| Completed | Afatinib Osimertinib Sequencing NIS NCT03370770 | Boehringer Ingelheim | — |
| Completed | A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung NCT03321695 | Hoffmann-La Roche | — |
| Completed | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell NCT03337698 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Recruiting | Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Cu NCT04926584 | Klinikum Esslingen | — |
| Completed | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Ce NCT03302234 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) NCT03345810 | AIO-Studien-gGmbH | Phase 2 |
| Completed | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) NCT03232593 | Hoffmann-La Roche | — |
| Completed | Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer NCT03331588 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 3 |
| Completed | Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC NCT03181308 | Tracon Pharmaceuticals Inc. | Phase 1 |
| Completed | Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung NCT03157089 | Boehringer Ingelheim | Phase 2 |
| Completed | Atezolizumab Immunotherapy in Patients With Advanced NSCLC NCT03102242 | Alliance Foundation Trials, LLC. | Phase 2 |
| Completed | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Partici NCT03285763 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreat NCT03261947 | Millennium Pharmaceuticals, Inc. | Phase 2 |